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Background. Respiratory viral infections (RVIs) are frequent complications of hematopoietic stem cell transplant (HSCT).
Surgical masks are a simple and inexpensive intervention that may reduce nosocomial spread.
Methods. In this prospective single-center study, we instituted a universal surgical mask policy requiring all individuals with
direct contact with HSCT patients to wear a surgical mask, regardless of symptoms or season. The primary endpoint was the inci-
dence of RVIs in the mask period (2010–2014) compared with the premask period (2003–2009).
Results. RVIs decreased from 10.3% (95/920 patients) in the premask period to 4.4% (40/911) in the mask period (P < .001).
Significant decreases occurred after both allogeneic (64/378 [16.9%] to 24/289 [8.3%], P = .001) and autologous (31/542 [5.7%] to
16/622 [2.6%], P = .007) transplants. After adjusting for multiple covariates including season and year in a segmented longitudinal
analysis, the decrease in RVIs remained significant, with risk of RVI of 0.4 in patients in the mask group compared with the premask
group (0.19–0.85, P = .02). In contrast, no decrease was observed during this same period in an adjacent hematologic malignancy
unit, which followed the same infection control practices except for the mask policy. The majority of this decrease was in parain-
fluenza virus 3 (PIV3) (8.3% to 2.2%, P < .001).
Conclusions. Requiring all individuals with direct patient contact to wear a surgical mask is associated with a reduction in RVIs,
particularly PIV3, during the most vulnerable period following HSCT.
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Respiratory viral infections (RVIs) are a significant complica-
tion of hematopoietic stem cell transplant (HSCT), affecting
up to 30% of patients [1–3]. In addition to causing rhinitis,
cough, and other symptoms, 25%–40% of cases progress to
lower respiratory tract infection [4, 5], with associated mortality
as high as 20%–40% [6–8].
Because HSCT recipients are immunocompromised and
tightly cohorted, they are vulnerable to nosocomial spread.
For example, there have been a number of reports of clusters
or outbreaks of parainfluenza virus type 3 (PIV3) within
HSCT units [5, 9–12]. In many of these cases, molecular epide-
miologic analyses have traced these outbreaks to a single or
handful of strains that spread through person-to-person trans-
mission [13–18].
While standard infection control procedures serve an essen-
tial role in curtailing RVIs [7, 19]. it is hypothesized that they
may be insufficient to prevent the nosocomial spread of PIV3
[10]. This is because patients (or caregivers or providers) with
PIV3 may shed virus, yet be asymptomatic [10, 12, 14–16],
and are therefore missed by standard droplet precautions that
focus on symptomatic patients. Similarly, strategies that in-
crease infection control measures during the winter influenza
and respiratory syncytial virus (RSV) seasons neglect PIV3,
which peaks in the summer [5, 9, 11–15, 17, 20].
In 2009, our HSCT unit experienced a higher-than-average
incidence of RVI, prompting an exploration for means to better
prevent transmission. We hypothesized that instituting an in-
fection control protocol that requires universal surgical mask
usage year-round by all individuals in contact with patients
peritransplant would complement existing measures (eg, uni-
versal hand washing) and provide greater protection against
RVI transmission.
MATERIALS AND METHODS
Infection Control and Mask Protocol
Following approval from the Duke University Health System
institutional review board, we conducted a prospective inter-
ventional trial of the impact of universal surgical mask usage
on RVIs. This policy was added to standard infection control
practices as implemented and monitored by Duke Hospital
Epidemiology and Infection Control (Figure 1). The univer-
sal mask policy required all individuals with direct patient
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contact—medical and support staff, visitors, caregivers, and pa-
tients—to wear surgical masks (3M Standard Earloop Mask
1826) when within 3 feet of an HSCT patient. Similar masks
have been shown to reduce aerosol shedding of both coarse
(>5 µm) and fine (≤5 µm) virus particles [21]. Patients were re-
quired to wear masks when traveling outside of their room. Uni-
versal surgical mask usage was instituted in both the HSCT
inpatient (16 beds) and outpatient day hospital (40 beds)
units and associated waiting rooms. Compliance was reinforced
by nurses, who were trained during the designated “washout”
period, and monitored periodically by independent observers
using the same protocol as for monitoring hand hygiene com-
pliance [22]. Because the focus was on reducing nosocomial
transmission, patients or caregivers were not required to wear
masks when alone at home or alone in their private rooms.
Patient Population
Universal surgical mask usage was instituted 1 December 2009.
Allowing 6 weeks for implementation and washout, the mask
cohort included all patients transplanted between 12 January
2010 and 11 January 2014. This conservative washout period
would be expected to be significantly greater than the up to
7-day incubation period for the respiratory viral pathogens of
interest [23]. All patients who received a transplant between 1
December 2003 (the earliest date data were available in the
electronic record) and 30 November 2009 were considered the
premask cohort. Patients were observed from the start of condi-
tioning (pretransplant preparative chemotherapy and/or radia-
tion) to the completion of peritransplant care and discharge.
Conditioning, prophylaxis for graft-vs-host disease (GVHD), dis-
charge criteria, and other clinical protocols were unchanged over
the course of the study. There was not a significant change in the
number of beds in either the hematology/oncology unit or the
bone marrow transplant unit through the course of the study.
Microbiologic Sampling, Diagnosis, and Definitions
All patients with respiratory symptoms were tested via nasopha-
ryngeal wash, sputum culture, tracheal aspirate, or bronchoal-
veolar lavage. Presence of virus was determined by direct
fluorescence antigen (DFA) or culture (2003–2009), polymerase
chain reaction (PCR) (2011–present), or a combination of DFA,
culture, and limited PCR (2009–2011) for influenza A and B,
parainfluenza virus (PIV) types 1, 2, and 3, adenovirus, and
RSV. Because testing for metapneumovirus, rhinovirus, and co-
ronavirus was not performed until 2011, they were excluded
from analysis. Death due to RVI was determined by blinded
review of the medical record by 3 physicians.
Data was obtained from medical records, the Duke HSCT da-
tabase, and the Duke Enterprise Data Unified Content Explorer
database.
Figure 1. Infection control practices during “premask” and “postmask” period are as follows: (1) isolation precautions including use of gown and gloves when patients have
or are colonized with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), and use of gowns, gloves, and surgical masks if a
patient has symptoms of an upper respiratory tract infection; (2) hand washing, which includes both washing with soap before entering the outpatient or inpatient hemato-
poietic stem cell transplant (HSCT) units as well as additional hand washing or hand sanitization with an antibacterial alcohol-based foam before patient contact (of note, a
hospital-wide campaign for aggressive hand hygiene started in April 2009, although compliance in the bone marrow transplant unit has consistently been high, ie, 96% average
[range, 94%–98%]); (3) all single rooms and double-door entry systems to maintain the integrity of the high-efficiency particulate air (HEPA) filtration system for the HSCT
inpatient unit; in the outpatient unit/day hospital, patients are either seen in individual rooms if positive or suspected to have a communicable organism (eg, MRSA, VRE,
respiratory viral infection [RVI]) or 1 of 2 open treatment areas separated by curtains; (4) visitation policies limiting visitors with RVI symptoms; (5) universal vaccination of staff
against influenza; and (6) disinfection protocols with ammonia or bleach with or without Tru-D ultraviolet-C room disinfection. Of note, while the HSCT unit switched from
ammonia to bleach in March 2011, further changes took place between April 2012 and August 2014 as part of a hospital-wide study examining room disinfection protocols for
contact isolation rooms: ammonia was used from April 2012 to October 2012; bleach from November 2012 to May 2013; ammonia again from June 2013 to December 2013; and
bleach again from January 2014 to August 2014 (however, rooms of patients with Clostridium difficilewere always cleaned with bleach). The HSCT unit also began using Tru-D
in February 2011; as part of the above study, hospital-wide use of this machine was also regulated from April 2012 to August 2014 as follows: Tru-D was used from April 2012 to
October 2012, not used November 2012 to December 2013, and used again from January 2014 to July 2014.
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Statistical Analysis
Baseline characteristics were summarized as number (percent-
age) for categorical variables, and mean (standard deviation)
and median (range) for continuous variables. Differences in
continuous baseline characteristics between premask and
mask cohorts were examined using the Wilcoxon rank-sum
test for independent nonparametric samples, as all continuous
variables were not normally distributed, and differences in cat-
egorical baseline characteristics, incidence of RVIs, percentage
of positive test results, and deaths due to RVIs were examined
using the χ2 test or Fisher exact test, as appropriate.
To further investigate the effects of seasonal and year-to-year
variation in RVIs, we conducted a time-series analysis, in which
patient observation time was broken down in a longitudinal way
so that each interval signified a single season (spring, summer,
fall, or winter) and a single location (inpatient or outpatient/day
hospital). The number of intervals per patient ranged from 1 for
a patient who had all procedures and treatment as an outpatient
over the course of a single season, to 19 for a patient who was in
and out of the hospital over the course of several seasons.
To account for unequal numbers of observation points and
varying lengths of total observation time, a segmented negative
binomial model with an exchangeable correlation structure and
an exposure time of the total number of days of observation was
used to examine the incidence of RVI. Quasi-Akaike Informa-
tion Criterion analysis was used to determine the best correla-
tion structure [24, 25]. A segmented regression model was used
because this type of model may be able to explain apparent dif-
ferences due to external effects that cannot be quantified using
traditional multiple regression [26]. In this model, time was seg-
mented into days from the start of the study, and days postin-
tervention. Patients in the premask cohort were given a value of
0 for postintervention time. Patient demographic and clinical
variables were examined as covariates in the multivariate
model. Myeloablative conditioning, use of alemtuzumab, um-
bilical cord transplant, haploidentical transplant, and GVHD
were only relevant for allogeneic HSCT (allo-HSCT), so a
third level was added to these variables to indicate that an au-
tologous HSCT (auto-HSCT) was performed. This level was ex-
cluded in the fitting of most models due to collinearity with the
type of transplant variable, but by coding the variables like this,
no patients were excluded in any model.
The primary endpoint was the incidence of RVI during the
peritransplant period. Incidence of PIV3 was examined as a sec-
ondary endpoint because the majority of RVIs fell into this cat-
egory. Model results are presented as incidence rate ratios with
95% confidence intervals (CIs). CIs were calculated using robust
standard errors. No adjustments were made for multiple com-
parisons. Statistical analyses were conducted using SAS soft-
ware, version 9.4 (SAS Institute, Cary, North Carolina) and
Stata software, version 13.1 (StataCorp, College Station, Texas).
RESULTS
Patient Characteristics
Nine hundred twenty patients were included in the premask co-
hort and 911 in the mask cohort (Table 1). Groups were balanced
in terms of sex, though the mask cohort tended to be older (mean
age, 55 vs 50 years, P < .001) and included more patients with
multiple myeloma (P < .001); as a result, a greater proportion re-
ceived auto-HSCT (622/911 [68.3%] vs 542/920 [58.9%],
P < .001). Among allo-HSCT recipients, patients in the mask
cohort were less likely to have received mismatched donor trans-
plants (73/911 [25.3%] vs 133/920 [35.2%], P = .006), particularly
human leukocyte antigen–haploidentical transplants, although
they were more likely to have receivedmyeloablative conditioning
(172/289 [59.5] vs 196/378 [51.9%], P < .05).
Impact of Universal Mask Usage
The overall incidence of RVI dropped from 95 of 920 (10.3%) in
the premask cohort to 40 of 911 (4.4%) in the mask cohort
(P < .001; Table 2). This decrease was primarily in PIV3,
which dropped from 76 of 920 (8.3%) to 20 of 911 (2.2%)
(P < .001). There was also a decrease in RSV (16/920 [1.7%]
to 11/911 [1.2%]), although this was not significant. The inci-
dence of influenza A and B, PIV1 and PIV2, and adenovirus
were also too low (<1%) to make meaningful comparisons.
The decrease in RVIs was significant among both allo-HSCT
(64/378 [16.9%] to 24/289 [8.3%], P = .001) and auto-HSCT pa-
tients (31/542 [5.7%] to 16/622 [2.6%], P = .007). Similarly,
Table 1. Baseline Patient Characteristics
Characteristic
Study Group
P ValueaPremask (n = 920) Mask (n = 911)
Male sex 536 (58.3) 525 (57.6) .78
Age, y, mean (SD) 50 (12.7) 54.7 (12.3) <.001
Age, y, median (range) 52 (19–79) 57 (18–81)
Disease <.001
Leukemia 237 (25.8) 186 (20.4)
Lymphoma 264 (28.7) 209 (22.9)
PCD 291 (31.6) 428 (47)
MDS/MPD 62 (6.7) 51 (5.6)
Other 66 (7.2) 37 (4.1)
Previous transplant 15 (1.6) 12 (1.3) .58
Type of transplant <.001
Autologous HSCT 542 (58.9) 622 (68.3)
Allogeneic HSCT 378 (41.1) 289 (31.7)
Myeloablativeb 196 (51.9) 172 (59.5) .05
Alemtuzumabb 152 (40.2) 99 (34.3) .12
Mismatchb 133 (35.2) 73 (25.3) .006
Umbilical cordb 73 (19.3) 51 (17.6)
Haploidenticalb 60 (15.9) 22 (7.6)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: cord, cord blood donor; haploidentical, human leukocyte antigen–haploidentical
donor; HSCT, hematopoietic stem cell transplant; MDS, myelodysplastic syndrome; MPD,
myeloproliferative disorder; PCD, plasma cell dyscrasia; SD, standard deviation.
a Wilcoxon rank-sum test for continuous variables and χ2 test for categorical variables.
b Presented as percentage of patients who received allogeneic HSCT.
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both allo-HSCT and auto-HSCT patients experienced large de-
creases in PIV3 (allo-HSCT: 49/378 [13.0%] to 12/289 [4.2%],
P < .001; auto-HSCT: 27/542 [5.0%] to 8/622 [1.3%], P < .001).
Concurrent with this decrease, the rate of death secondary to
RVI dropped in the mask cohort (all patients: 11/920 [1.2%]
to 0/911 [0%], P = .001; allo-HSCT: 9/378 [2.4%] to 0%,
P = .006, auto-HSCT: 2/542 [0.4%] to 0%, P = .217).
The decision to test for viral pathogens was dependent on
patient signs and symptoms and clinician concern for viral in-
fection. It was not surprising, therefore, that concurrent with
the decrease in RVIs, fewer viral tests were performed in the
mask period. However, despite the increased sensitivity of
PCR-based tests in the mask period, the proportion of positive
test results was lower: 29% of tests were positive premask
(95 positive of 328 tests), compared with 15% (25/162) from
12 January 2010 to 11 January 2013 (P = .002; data on total
tests performed were not available for the last year, and thus
are not included in this calculation). This suggests that testing
practices for RVIs was more aggressive in the mask period, and
the rate of RVIs was truly lower.
Time-Series Analysis to Adjust for Seasonal and Yearly Variation
and Other Potential Confounders
There were substantial seasonal and yearly variations in the in-
cidence of RVI (Figure 2). For example, PIV tended to peak in
the summer, whereas RSV and influenza peaked in the winter.
Some years (eg, 2005) had particularly severe outbreaks of PIV
whereas other years (eg, 2008) saw few or no cases. To rule out
the possibility that seasonal or yearly variations confounded our
analysis, we conducted a time-series analysis to adjust for the
covariates of season and year, as well as age, location, type of
transplant, and, for allo-HSCT, conditioning intensity, T-cell
depletion, donor, and GVHD (Table 3). Using this model,
mask use was estimated to reduce the risk of RVI by 60%
after adjusting for covariates (P = .017). Other significant vari-
ables were season, conditioning intensity, and GVHD.
We also used this model to evaluate the interaction between
season and mask use and found that the impact of the mask in-
tervention was greatest in the summer (P = .001; Supplementary
Table 1). We found no interaction between location (inpatient vs
outpatient) and mask use (Supplementary Table 2), suggesting
Table 2. Incidence of Respiratory Viral Infections
All Patients (N = 1831)
Study Group
P ValueaPremask (n = 920) Mask (n = 911)
Any virus (excluding metapneumovirus) 95 (10.3) 40 (4.4) <.001
Influenza A 5 (0.5) 4 (0.4)
Influenza B 1 (0.1) 1 (0.1)
Parainfluenza (any) 78 (8.5) 22 (2.4) <.001
Parainfluenza 1 0 (0) 1 (0.1)
Parainfluenza 2 3 (0.3) 1 (0.1)
Parainfluenza 3 76 (8.3) 20 (2.2) <.001
Adenovirus 0 (0) 5 (0.5)
Respiratory syncytial virus 16 (1.7) 11 (1.2) .35
Allo-HSCT Patients (n = 667)
Study Group
P ValuePremask (n = 378) Mask (n = 289)
Any virus (excluding metapneumovirus) 64 (16.9) 24 (8.3) .001
Influenza A 4 (1.1) 3 (1)
Influenza B 0 (0) 0 (0)
Parainfluenza (any) 51 (13.5) 14 (4.8) <.001
Adenovirus 0 (0) 3 (1)
Respiratory syncytial virus 14 (3.7) 5 (1.7)
Study Group
Auto-HSCT Patients (n = 1164) Premask (n = 542) Mask (n = 622) P Value
Any virus (excluding metapneumovirus) 31 (5.7) 16 (2.6) .007
Influenza A 1 (0.2) 1 (0.2)
Influenza B 1 (0.2) 1 (0.2)
Parainfluenza (any) 27 (5) 8 (1.3) <.001
Adenovirus 0 (0) 2 (0.3)
Respiratory syncytial virus 2 (0.4) 6 (1)
Data are presented as No. (%).
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplant; auto-HSCT, autologous hematopoietic stem cell transplant.
a χ2 test.
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that the impact of mask use was not dependent on location.
We also found no interaction between location and type of
transplant (allo- vs auto-HSCT) (Supplementary Table 3).
Analyses were also performed looking at PIV3 as the endpoint
of interest (Supplementary Table 4): mask use was estimated
to reduce the risk of PIV3 by 69% after adjusting for covariates
(P = .016).
Comparisons With the Rest of the Hospital
To evaluate the impact of the addition of universal mask usage
to standard infection control procedures, we compared the oc-
currence of PIV3 in the HSCT population to that of the rest of
the hospital (which only used masks as part of standard droplet
precautions with symptomatic patients) (Figure 3). In the pre-
mask period, PIV3 among HSCT patients tracked closely with
the PIV3 in the rest of the hospital. However, after the universal
surgical mask policy was instituted, the number of PIV3 infec-
tions dropped significantly among HSCT patients, whereas it
remained high in the rest of the hospital. Before universal
mask usage, HSCT patients accounted for 32% (76/233) of
all hospital-wide PIV3 infections; this dropped to just 10.4%
(20/192) after implementation (P < .001).
We also compared the HSCT population to a neighboring he-
matologic malignancy unit that had identical infection control
practices with the exception of universal surgical mask usage
(Supplementary Figure 1): RVI and PIV3 in the neighboring
unit actually increased over time, whereas they decreased in
the HSCT population (data from the neighboring unit were
not available prior to 1 July 2006).
Compliance
Compliance with universal surgical mask usage was extremely
high (>99% among healthcare providers [414 compliant per 415
observations] and 98% among patients/caregivers [193/197]).
Figure 2. The incidence of respiratory viral infections (RVIs) after hematopoietic stem cell transplant by season and year. The dotted line represents when the universal
surgical mask policy was instituted, after which the number of RVIs dropped significantly. Parainfluenza virus predominated and tended to cluster in the summertime. Abbre-
viation: RSV, respiratory syncytial virus.
Table 3. Negative Binomial Model Results for the Incidence of Any Viral
Infection
Predictor IRR (95% CI) P Value
Age at HSCT, y 1.000 (.988–1.012) .97
Season
Spring vs fall 2.597 (1.286–5.245) .008
Summer vs fall 3.137 (1.735–5.674) <.001
Winter vs fall 2.186 (1.062–4.502) .03
Year of HSCT 1.106 (.505–2.423) .80
Location: inpatient vs outpatient 1.436 (.913–2.259) .12
Type of transplant: allo-HSCT vs auto-HSCT 1.112 (.596–2.076) .74
For allo-HSCT
Conditioning intensity: myeloablative vs
not myeloablative
0.394 (.226–.689) .001
T-cell depletion: alemtuzumab vs no
alemtuzumab
0.904 (.479–1.705) .76
Donor: umbilical cord vs not umbilical cord 1.037 (.599–1.794) .90
Donor: haploidentical vs not haploidentical 1.037 (.642–1.675) .88
GVHD vs no GVHD 1.418 (1.010–1.990) .04
Mask use: mask vs premask (adjusted) 0.398 (.187–.848) .02
Mask use: mask vs premask (unadjusted) 0.484 (.347–.675) <.001
The adjusted model also controls for the time from the start of the study (1 December 2003)
and the time from the start of the intervention (12 January 2010) in days. The unadjusted
model includes only mask use. After controlling for potential year-to-year variation, the
season, conditioning intensity, presence of GVHD, and mask use had a statistically
significant impact on RVI (bolded).
The bolded P values are for those variables that are significantly associated with incidence of
any viral infection.
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplant; auto-HSCT,
autologous hematopoietic stem cell transplant; CI, confidence interval; GVHD, graft-vs-
host disease; HSCT, hematopoietic stem cell transplant; IRR, incidence rate ratio; RVI,
respiratory viral infection.
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Compliance with hand hygiene was also consistently high (96%
among healthcare providers [5672/5934]; data not available for
patients/caregivers).
DISCUSSION
Although modern infection control practices have helped de-
crease viral infections and curtail outbreaks, RVIs remain prob-
lematic after HSCT [9, 11, 12]. Standard preventive methods
include strict hand hygiene, vaccination, active and early surveil-
lance, and contact and droplet isolation of symptomatic patients
[27, 28]. However, strategies that focus on symptoms do not ad-
dress the prolonged asymptomatic shedding of RVIs in immuno-
compromised patients, including PIV3 [10, 12, 14–16],which can
range from 5 to 121 days [10, 12, 14, 20]. It is therefore not sur-
prising that symptom-based surveillance and isolation policies
have been reported with mixed results [11, 12, 16]. In one pro-
longed outbreak of PIV3 at the Fred Hutchinson Cancer Research
Center, droplet isolation of aggressively screened symptomatic
patients did not impact the duration or severity of the outbreak
[16], as was the case at our institution in 2005. In contrast, more
success was seen when universal surgical mask usage was institut-
ed in response to a PIV3 outbreak at the Johns Hopkins Sidney
Kimmel Comprehensive Cancer Center [12].
Given its effectiveness in controlling an outbreak, universal
surgical mask usage shows promise as an inexpensive and
easy-to-implement preventative. In addition to directly stop-
ping transmission of viral particles, universal usage may drive
a cultural change in providers and patients, heightening aware-
ness of and attention to the importance of infection control.
This intervention may be readily applied to other HSCT pro-
grams, and in fact, some institutions already require everyone
to wear surgical masks during the peak winter influenza season
[12].However, as PIV3 is most common in the spring and sum-
mer months, and nosocomial outbreaks of PIV3 can be pro-
longed and extend beyond the typical season [11, 17], focus
on the winter neglects a significant proportion of RVIs.
By requiring universal surgical mask usage year-round, we
were able to significantly reduce RVIs after HSCT. The biggest
impact was on PIV3, which made up the majority of RVIs. Con-
sistent with the reported literature [2], we also found that
GVHD was associated with more RVIs (GVHD patients receive
additional immunosuppression including corticosteroids), and
myeloablative conditioning was associated with fewer RVIs
(these patients are generally healthier, ie, able to tolerate myeloa-
blative conditioning). Interestingly, our model did not find a sig-
nificant difference between allo-HSCT and auto-HSCT; however,
our model controls for inpatient/outpatient stay, taking into ac-
count the length of the interval. Because incidence of RVI after
allo-HSCT is 3 times that of auto-HSCT, and the length of stay
for allo-HSCT is 3 times that of auto-HSCT, controlling for
length of stay minimizes the impact of type of transplant.
A limitation of this study is the before-and-after design.
There were significant differences between cohorts, such as
the increased prevalence of plasma cell dyscrasia, and conse-
quently auto-HSCT, in the mask cohort. However, universal
surgical mask usage had a significant protective effect within
both the auto-HSCT and allo-HSCT subgroups. Whereas sea-
sonal and yearly variations in RVIs may also bias results, we
Figure 3. Parainfluenza virus 3 (PIV3) infections after hematopoietic stem cell transplant (HSCT) vs all other hospitalized patients (hospital). The dotted line represents when
universal surgical mask policy was instituted. Prior to the mask policy, PIV3 infections among HSCT patients tracked closely with those in the rest of the hospital; after
intervention, the number of PIV3 cases dropped dramatically among HSCT patients but remained elevated in the rest of the hospital (P < .001).
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found no parallel decrease in the rest of the hospital. Thus, it
seems unlikely that natural variation in the rate of RVIs in the
community accounts for the observed decrease. This is support-
ed by our time-series analysis, which found a 60% decrease in
the risk of RVIs in the mask period after accounting for the co-
variates of season and year, in addition to disease, type of trans-
plant, and other variables. Additionally, differences in detection
methods in the premask period (predominantly viral culture
and DFA) vs the postmask period (PCR) could impact the re-
sults. However, as PCR is known to be at least 30% more sen-
sitive at detecting viral pathogens compared with DFA and
culture, depending on the pathogen, without sacrificing specif-
icity [29, 30], we would expect a bias toward the null. The true
effect size of the mask intervention thus may be underrepre-
sented in the current study.
Our interventional study was designed in direct response to a
rise in RVI in 2009, which could render it susceptible to effects
seen due to regression to the mean. To mitigate this possibility,
we collected data over an extended period of 4 full years follow-
ing implementation of universal mask usage, rather than exam-
ining simply 1 season or 1 year. We considered the possibility of
testing bias resulting in reduced vigilance in screening for RVIs
during the mask period. However, the lower proportion of
positive test results in the mask period suggests that testing
is more frequent in the mask period—that is, undertesting
would not explain the decrease in RVIs. We also considered
the possibility that, over the course of the study period, im-
proved hospital-wide infection control efforts over the 10-
year span of the study were responsible for the reduction in
RVI rates in HSCT patients. However, a concurrent reduction
in RVIs was not observed in either an adjacent non-HSCT he-
matologic malignancy unit or hospital-wide. Moreover, in-
creasing use of more sensitive and specific PCR-based viral
diagnostic testing would be expected to increase the detection
of RVI during the universal mask period, as was seen in the ad-
jacent hematologic malignancy unit. In contrast, we observed a
decrease in RVIs despite this increased sensitivity, raising the
possibility that we are underestimating the protective effect of
universal mask usage.
In conclusion, we have shown that universal surgical mask
usage, which requires all individuals in inpatient and outpatient
HSCT facilities with direct patient contact to wear surgical
masks regardless of symptoms or season, is associated with a
significant decrease in clinically significant RVI, particularly
PIV3. This suggests that universal surgical mask usage could
be a potent adjunct to standard infection control practices in
bone marrow transplant units.
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